Volume 152, Issue 1, Pages 61-67 (January 2019) Real-world effectiveness of bevacizumab based on AURELIA in platinum-resistant recurrent ovarian cancer (REBECA): A Korean Gynecologic Oncology Group study (KGOG 3041) Jung-Yun Lee, Jeong-Yeol Park, Sang Yoon Park, Jeong-Won Lee, Jae Weon Kim, Yong Beom Kim, Dae Hoon Jeong, Kwang-Beom Lee, Tae-Hun Kim, In Ho Lee, Min Chul Choi, Ki Hyung Kim, Yong-Man Kim, Yong Jae Lee, Sokbom Kang, Eric Pujade-Lauraine Gynecologic Oncology Volume 152, Issue 1, Pages 61-67 (January 2019) DOI: 10.1016/j.ygyno.2018.10.031 Copyright © 2018 Terms and Conditions
Fig. 1 Patient disposition. W-P, weekly paclitaxel; Topo, topotecan; AE, adverse event; BEV, bevacizumab; CT, chemotherapy. Gynecologic Oncology 2019 152, 61-67DOI: (10.1016/j.ygyno.2018.10.031) Copyright © 2018 Terms and Conditions
Fig. 2 Survival according to chemotherapy partner. Gynecologic Oncology 2019 152, 61-67DOI: (10.1016/j.ygyno.2018.10.031) Copyright © 2018 Terms and Conditions
Fig. 3 Summary of treatment exposure. Gynecologic Oncology 2019 152, 61-67DOI: (10.1016/j.ygyno.2018.10.031) Copyright © 2018 Terms and Conditions